Department of Chemical and Biological Engineering, University of Sheffield, Sheffield, United Kingdom; Analytical Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Cambridge, United Kingdom.
Analytical Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Cambridge, United Kingdom.
J Chromatogr A. 2022 May 10;1670:462944. doi: 10.1016/j.chroma.2022.462944. Epub 2022 Mar 9.
Monoclonal antibodies (mAbs) are extremely complex due to the presence of structural modifications resulting from enzymatic and chemical reactions such as glycosylation, glycation, deamidation, isomerisation, oxidation, aggregation and fragmentation. Size and charge variants analysis are carried out from the early stages of drug development throughout product lifetime to investigate product degradation pathways and optimise process conditions. However, conventional analytical workstreams for size and charge variant characterization are both time and sample demanding, requiring the application of multiple analytical methods. This study presents the development of a novel 2D-LC/MS approach combining both aggregate and charge variant profiling of a mAb candidate in a single method. Aggregate quantification was performed in the first dimension (D) by size exclusion chromatography SEC, followed by online fraction transfer of the monomer peak to the second dimension (D) by a heart-cutting for charge variant analysis by cation exchange chromatography (CEX). Aiming to maximise the information obtained from minimal sample and time required for analysis, a salt-based separation with UV detection was developed for supporting the processing of a large number of samples to facilitate high-throughput process development (HTPD). In addition, a mass spectrometry (MS) compatible SEC-CEX separation was developed enabling online charge variant peak identification. This study presented the ability to multiplex mAb size and charge variants analysis by coupling SEC with CEX in a 2D-LC set-up. To date, this is the first 2D SEC-CEX-UV(-MS) application for intact mAb analysis.
单克隆抗体(mAbs)非常复杂,因为存在结构修饰,这些修饰是由酶和化学反应引起的,如糖基化、糖化、脱酰胺、异构化、氧化、聚集和片段化。大小和电荷变异体分析在药物开发的早期阶段进行,贯穿产品生命周期,以研究产品降解途径并优化工艺条件。然而,传统的大小和电荷变异体分析工作流程都需要大量的时间和样品,需要应用多种分析方法。本研究提出了一种新的二维 LC/MS 方法,该方法结合了单克隆抗体候选物的聚集和电荷变异体分析,在单一方法中同时进行。在第一维(D)中通过尺寸排阻色谱 SEC 进行聚集定量,然后通过在线分馏将单体峰转移到第二维(D),通过阳离子交换色谱(CEX)进行电荷变异体分析。为了从最小的样品中获得最大的信息,并减少分析所需的时间,开发了一种基于盐的分离方法,具有紫外检测功能,以支持处理大量样品,从而促进高通量工艺开发(HTPD)。此外,还开发了一种与 MS 兼容的 SEC-CEX 分离方法,可实现在线电荷变异体峰识别。本研究通过将 SEC 与 CEX 耦合在二维 LC 系统中,展示了同时分析 mAb 大小和电荷变异体的能力。迄今为止,这是首次将二维 SEC-CEX-UV(-MS)应用于完整 mAb 分析。